Skip to main content

The independent medical news service

Kidney cancer

21-02-2020 | Oncology | News | Article

Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial.

This independent news story was supported by an educational grant from Pfizer and Merck KGaA

08-01-2020 | Oncology | News | Article

PD-1 inhibition may result in better solid tumor survival than PD-L1 inhibition

Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.

07-01-2020 | Oncology | News | Article

Tumor microenvironment changes implicated in clear cell RCC obesity paradox

Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.

13-12-2019 | Oncology | News | Article

Sarcopenia could predict the immune-related toxicity risk associated with nivolumab

Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.

21-11-2019 | Oncology | News | Article

Data support immunotherapy combination for RCC with variant histology, sarcomatoid features

A meaningful proportion of patients with advanced renal cell carcinoma with variant histology or sarcomatoid differentiation respond to the immunotherapy combination of atezolizumab and bevacizumab without experiencing severe toxicity, phase II study data show.

22-10-2019 | Oncology | News | Article

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

21-10-2019 | Oncology | News | Article

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Oncology | News | Article

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.

17-10-2019 | Oncology | News | Article

Neoadjuvant nivolumab tested for metastatic RCC

Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.

15-10-2019 | Oncology | News | Article

TITAN-RCC showcases tailored immunotherapy approach

Results from the TITAN-RCC trial add support for the use of ipilimumab alongside nivolumab in patients with intermediate- or high-risk advanced renal cell carcinoma, showing that a personalized strategy is feasible for nonresponders.

14-10-2019 | Oncology | News | Article

SORCE rules out adjuvant sorafenib for RCC

Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.

08-10-2019 | Oncology | News | Article

JAVELIN Renal 101 subanalyses add to evidence for avelumab plus axitinib

Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.

25-09-2019 | Oncology | News | Article

Avelumab indication extended in Europe to advanced RCC

Find out more here

02-09-2019 | Oncology | Main feed | Article

Elevated cardiovascular risk seen in survivors of most common cancers

Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.

21-08-2019 | Oncology | News | Article

Long-term benefit of nivolumab plus ipilimumab shown in advanced RCC

Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

01-07-2019 | Oncology | News | Article

Targeted therapy can benefit complex patients with advanced RCC

Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.

26-06-2019 | Oncology | News | Article

Nivolumab has ‘limited’ CNS activity in RCC patients with brain metastases

In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.

25-06-2019 | Oncology | News | Article

JAVELIN Renal 101 biomarker analysis may help personalize patient care

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

18-06-2019 | Oncology | News | Article

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

Image Credits